Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab

NCT00536640 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

224

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Erlotinib
DRUG: Bevacizumab
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

Aktion Bronchialkarzinom e.V.

Collaborators

[object Object]